ERBB2 and breast carcinoma: Since the bioinformatics showed that there was a correlation between PARP1 and BRCA1/2, and at the same time, a correlation with ERBB2 in basal; such results indicate that those breast cancer patients can receive not only PARP inhibitors, but also Anti-HER2 Monoclonal Antibodies as therapeutic drugs.